eGene and Daiichi Pure Chemicals Co., Ltd. Enter into Three Year Distribution Relationship in Japan
IRVINE, Calif., Jun 27, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, announced today that it has entered into a three year distribution agreement with Daiichi Pure Chemicals Co., Ltd., to promote and sell eGene's HDA-GT12 system in Japan.
Dr. Ming S. Liu, CEO of eGene, noted: "We are very pleased to work with Daiichi Pure Chemicals Co., Ltd. Both of us have seen the wonderful business opportunities for our genetic analyzer's use in the area Daiichi serves, and eGene believes that Daiichi's expertise will suit our product very well."
Daiichi Pure Chemicals Co., Ltd. is a subsidiary of Daiichi Sankyo Co., Ltd., the second largest pharmaceutical company in Japan.
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures the quality of fragmented cRNA. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
